Skip to main content

Table 2 Results of logistic regression analysis for clinical factors and response to CCCRT

From: ERCC1 mRNA levels can predict the response to cisplatin-based concurrent chemoradiotherapy of locally advanced cervical squamous cell carcinoma

 

B

SE

Wald

P value

OR

95% CI for OR

Age

−0.104

0.064

2.599

0.107

0.902

0.795-1.023

Histologic grade

−0.450

1.090

0.171

0.680

0.638

0.075-5.399

Tumor size

2.908

1.567

3.445

0.063

18.315

0.850-394.766

Parametrial invasion

2.773

1.878

2.180

0.140

16.011

0.403-635.705

Lymph node status

−0.274

1.060

0.067

0.796

0.760

0.095-6.074

FIGO stage

2.471

1.797

1.891

0.169

11.836

0.349-400.843

Hemoglobin levels at diagnosis

−0.326

1.252

0.068

0.795

0.722

0.062-8.398

Platelets at diagnosis

−0.166

1.309

0.016

0.899

0.847

0.065-11.013

ERCC1 mRNA status

5.003

1.408

12.624

0.000

148.869

9.424-2351.736

Chemotherapy cycles

−0.932

1.073

0.755

0.385

0.394

0.048-3.225

  1. Abbreviations: CCCRT cisplatin-based concurrent chemoradiotherapy, B regression coefficient, SE standard error, Wald Wald value, OR odds ratio, CI confidence interval, FIGO International Federation of Gynecology and Obstetrics, ERCC1 excision repair cross-complementation group 1.